TEDCO Supports Sirius Biotech Ventures Through Concept Capital Program

Frederick-based company is developing an innovative platform to enhance drug-discovery efficiency

COLUMBIA, Md. (September 15, 2026) - TEDCO, Maryland's economic engine for technology companies, announced a $25,000 investment in Sirius Biotech Ventures, a company specializing in the discovery and development of novel medications, through its Concept Capital Program.

"This support from TEDCO validates our innovative approach to tackling resistance to KRAS-targeted therapies," said Frantz Jean-François, PhD, CEO of Sirius Biotech Ventures. "With this funding, we can accelerate our discovery program and identify promising combination therapies designed to extend the durability of clinical response to KRAS inhibitors."

Based in Frederick, Md., Sirius Biotech Ventures aims to build a platform that integrates high-content phenotypic and functional profiling with mass spectrometry to improve the efficiency of drug discovery. The discovery-stage oncology company is developing companion small-molecule drug candidates designed to overcome resistance to KRAS inhibitors and extend the duration of clinical response. By combining clinically relevant models of KRAS inhibitor resistance with data-driven profiling and diverse natural-product chemistry, Sirius aims to identify validated KRAS combination assets suitable for licensing within 18-24 months.

"Sirius Biotech Ventures is tackling a gap in KRAS-targeted cancer therapy with an innovative approach," said Justin Ferguson, innovation manager, Venture Development, TEDCO. "Supporting innovations like this is central to TEDCO's mission of strengthening Maryland's life sciences ecosystem, and we hope to see this funding fuel the company's continued growth."

TEDCO's Concept Capital program was created to provide critical early-stage funding for tech companies in need of assistance to further launch and grow their business, allowing Maryland to become a hub for entrepreneurial success. For more information about the Concept Capital program, please visit tedcomd.com/funding/concept-capital.

"Maryland continues to attract world-class scientific talent tackling some of the toughest challenges in medicine, and Sirius Biotech Ventures is a strong example of that," said Troy LeMaile-Stovall, CEO of TEDCO. "Companies like Sirius benefit from Maryland's unique life sciences ecosystem - anchored by federal institutions such as the National Institutes of Health and the U.S. Food and Drug Administration and supported by leading academic partners and a highly skilled workforce. TEDCO is proud to help fuel this kind of innovation as it moves from the lab toward real solutions for cancer patients."